CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and
pharmacodynamics of CyPep-1 when administered directly into malignant tumors in monotherapy
and in combination with anti-PD-1 antibody pembrolizumab. Additionally, the trial will
monitor anti-tumor effects on both injected lesions and distant non-injected deposits.